Programmed Death Receptor-1/Programmed Death Receptor Ligand-1 Blockade after Transient Lymphodepletion To Treat Myeloma

被引:82
作者
Kearl, Tyce J. [1 ]
Jing, Weiqing [2 ]
Gershan, Jill A. [2 ]
Johnson, Bryon D. [1 ,2 ]
机构
[1] Med Coll Wisconsin, Dept Microbiol & Mol Genet, Milwaukee, WI 53226 USA
[2] Med Coll Wisconsin, Dept Pediat, Div Hematol Oncol Transplant, Milwaukee, WI 53226 USA
关键词
CD8(+) T-CELLS; MULTIPLE-MYELOMA; HOMEOSTATIC PROLIFERATION; METASTATIC MELANOMA; IN-VIVO; ADOPTIVE IMMUNOTHERAPY; EPITHELIAL-CELLS; IMMUNE-RESPONSE; DENDRITIC CELLS; PD-L1; BLOCKADE;
D O I
10.4049/jimmunol.1202005
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Early phase clinical trials targeting the programmed death receptor-1/ligand-1 (PD-1/PD-L1) pathway to overcome tumor-mediated immunosuppression have reported promising results for a variety of cancers. This pathway appears to play an important role in the failure of immune reactivity to malignant plasma cells in multiple myeloma patients, as the tumor cells express relatively high levels of PD-L1, and T cells show increased PD-1 expression. In the current study, we demonstrate that PD-1/PD-L1 blockade with a PD-L1 specific Ab elicits rejection of a murine myeloma when combined with lymphodepleting irradiation. This particular combined approach by itself has not previously been shown to be efficacious in other tumor models. The antitumor effect of lymphodepletion/anti-PD-Li therapy was most robust when tumor Ag-experienced T cells were present either through cell transfer or survival after nonmyeloablative irradiation. In vivo depletion of CD4 or CD8 T cells completely eliminated antitumor efficacy of the lymphodepletion/anti-PD-Li therapy, indicating that both T cell subsets are necessary for tumor rejection. Elimination of myeloma by T cells occurs relatively quickly as tumor cells in the bone marrow were nearly nondetectable by 5 d after the first anti-PD-Li treatment, suggesting that anti-myeloma reactivity is primarily mediated by preactivated T cells, rather than newly generated myeloma-reactive T cells. Anti-PD-Li plus lymphodepletion failed to improve survival in two solid tumor models, but demonstrated significant efficacy in two hematologic malignancy models. In summary, our results support the clinical testing of lymphodepletion and PD-1/PD-L1 blockade as a novel approach for improving the survival of patients with multiple myeloma.
引用
收藏
页码:5620 / 5628
页数:9
相关论文
共 58 条
[1]  
BERENSON JR, 1975, J IMMUNOL, V115, P234
[2]   PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells [J].
Blank, C ;
Brown, I ;
Peterson, AC ;
Spiotto, M ;
Iwai, Y ;
Honjo, T ;
Gajewski, TF .
CANCER RESEARCH, 2004, 64 (03) :1140-1145
[3]   Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion [J].
Blank, Christian ;
Mackensen, Andreas .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2007, 56 (05) :739-745
[4]   Lymphoid reconstitution after autologous PBSC transplantation with FACS-sorted CD34+ hematopoietic progenitors [J].
Bomberger, C ;
Singh-Jairam, M ;
Rodey, G ;
Guerriero, A ;
Yeager, AM ;
Fleming, WH ;
Holland, HK ;
Waller, EK .
BLOOD, 1998, 91 (07) :2588-2600
[5]   Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration [J].
Bracci, Laura ;
Moschella, Federica ;
Sestili, Paola ;
La Sorsa, Valentina ;
Valentini, Mara ;
Canini, Irene ;
Baccarini, Sara ;
Maccari, Sonia ;
Ramoni, Carlo ;
Belardelli, Filippo ;
Proietti, Enrico .
CLINICAL CANCER RESEARCH, 2007, 13 (02) :644-653
[6]   Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer [J].
Brahmer, Julie R. ;
Tykodi, Scott S. ;
Chow, Laura Q. M. ;
Hwu, Wen-Jen ;
Topalian, Suzanne L. ;
Hwu, Patrick ;
Drake, Charles G. ;
Camacho, Luis H. ;
Kauh, John ;
Odunsi, Kunle ;
Pitot, Henry C. ;
Hamid, Omid ;
Bhatia, Shailender ;
Martins, Renato ;
Eaton, Keith ;
Chen, Shuming ;
Salay, Theresa M. ;
Alaparthy, Suresh ;
Grosso, Joseph F. ;
Korman, Alan J. ;
Parker, Susan M. ;
Agrawal, Shruti ;
Goldberg, Stacie M. ;
Pardoll, Drew M. ;
Gupta, Ashok ;
Wigginton, Jon M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) :2455-2465
[7]   Increased Level of both CD4+FOXP3+ Regulatory T Cells and CD14+HLA-DR-/low Myeloid-Derived Suppressor Cells and Decreased Level of Dendritic Cells in Patients with Multiple Myeloma [J].
Brimnes, M. K. ;
Vangsted, A. J. ;
Knudsen, L. M. ;
Gimsing, P. ;
Gang, A. O. ;
Johnsen, H. E. ;
Svane, I. M. .
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2010, 72 (06) :540-547
[8]   Blockade of programmed death-1 Ligands on dendritic cells enhances T cell activation and cytokine production [J].
Brown, JA ;
Dorfman, DM ;
Ma, FR ;
Sullivan, EL ;
Munoz, O ;
Wood, CR ;
Greenfield, EA ;
Freeman, GJ .
JOURNAL OF IMMUNOLOGY, 2003, 170 (03) :1257-1266
[9]   Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses [J].
Butte, Manish J. ;
Keir, Mary E. ;
Phamduy, Theresa B. ;
Sharpe, Arlene H. ;
Freeman, Gordon J. .
IMMUNITY, 2007, 27 (01) :111-122
[10]   Homeostasis-stimulated proliferation drives naive T cells to differentiate directly into memory T cells [J].
Cho, BK ;
Rao, VP ;
Ge, Q ;
Eisen, HN ;
Chen, JZ .
JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (04) :549-556